Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study

• Published in: Medicine (Baltimore) 2019-06, Vol.98 (26), p.e15947-e15947
• Main Authors: Corominas, Héctor, Alegre, Cayetano, Narváez, Javier, Fernández-Cid, Carlos Marras, Torrente-Segarra, Vicenç, Gómez, Manuel Rodríguez, Pan, Francisco Maceiras, Morlà, Rosa María, Martínez, Fernando José Rodríguez, Gómez-Centeno, Antoni, Ares, Laura Losada, Molina, Rocío González, González-Albo, Silvia Paredes, Dalmau-Carolà, Joan, Pérez-García, Carolina, Álvarez, Ceferino Barbazán, Ercole, Liliana, Terrancle, Maria Ángeles
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - physiopathology; Arthritis, Rheumatoid - psychology; Arthritis, Rheumatoid - therapy; Biomarkers - metabolism; C-Reactive Protein - metabolism; Depression - physiopathology; Depression - therapy; Fatigue - etiology; Fatigue - physiopathology; Fatigue - psychology; Fatigue - therapy; Female; Humans; Male; Middle Aged; Observational Study; Prospective Studies; Retreatment; Sleep; Treatment Outcome; Tumor Necrosis Factor-alpha - therapeutic use
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000015947

To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 ± 12.5 years, disease duration 8.7 ± 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 ± 4.0 (P